Biotech News
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
ir.protaratx.com2026-05-13 12:11 EST
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data from